Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.30
Bid: 8.20
Ask: 8.40
Change: 0.00 (0.00%)
Spread: 0.20 (2.439%)
Open: 8.30
High: 8.30
Low: 8.30
Prev. Close: 8.30
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Meatable Announces US$ 47 Million Financing

23 Mar 2021 15:00

RNS Number : 2282T
Agronomics Limited
23 March 2021
 

23 March 2021

 

Agronomics Limited

("Agronomics" or the "Company")

Investee Company Update: Meatable Announces US$ 47 Million Series A Financing

 

Agronomics, the leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat, is pleased to announce portfolio company Meatable B.V. "Meatable" has closed a US$ 47 million Series A funding round, with participation from new investors Section 32, Jeffrey Leiden and strategic investor DSM, as well as support from existing investors, BlueYard Capital, Humboldt and Taavet Hinrikus in addition to Agronomics.

As stated in the announcement dated 18th February 2021, Agronomics invested € 2 million in this Series A round, for 1,197 preferred shares. Agronomics holds 4,752 preferred shares in Meatable, representing an equity ownership on a fully diluted basis, of 5.70%. Subject to audit, Agronomics will now carry this position in its accounts at a book value of € 7.95 million, representing an unrealised gain on cost of € 2.95 million.

The full announcement is set out below with no material changes or adjustments:

Meatable Raises $47 Million Series A to Continue Scaling Trajectory and Expand Its Product Portfolio with Beef

Consortium of life sciences and food investors Section 32, DSM Venturing, Dr. Rick Klausner, Dr. Jeffrey Leiden and existing investors was formed to optimally support Meatable for its next phase of growth

AMSTERDAM, March 23rd - Meatable, the cultivated meat startup, has closed $47 million USD in its Series A funding round, bringing the company's total funding to $60 million. Meatable finalized its first showcase product in 2020 and aims to use the new funds to advance smallscale production at the Biotech Campus Delft and to diversify its product portfolio.

The consortium consists of Dr. Rick Klausner Section 32, Jeffrey Leiden, and DSM, and includes existing investors, such as BlueYard Capital, Agronomics, Humboldt, and Taavet Hinrikus, showing continued support. They recognize the positive impact cultivated meat will have on climate change, see the trillion-dollar potential of the cultivated meat marketplace, and are betting on Meatable to solve the industry's scalability and speed-to-market challenges with its patented opti-ox™ technology.

Dr. Rick Klausner, former director of the US National Cancer Institute and former Executive Director of Global Health at the Bill & Melinda Gates Foundation, sees great potential in Meatable and its technology.

"We are committed to joining Meatable in its mission to address the world's most pressing challenges. We see a smart start-up that has accomplished a lot in a short amount of time. They have a great team and game-changing technology that can address the challenges around the global food insecurity issues our planet is facing," said Klausner. "They have all the right ingredients to become the leading choice for sustainably and efficiently produced meat."

Meatable's proprietary technology enables it to use pluripotent cells to replicate the natural process of fat and muscle growth, in proportions that emulate traditional cuts of meat. The entire process takes only weeks, where it takes years to grow a live animal.

"To be able to meet the growing demand for meat worldwide, we need breakthrough solutions. Cultivated meat has the potential to continue to produce the product we love - meat - using a much more efficient production process. Having Rick Klausner, Jeffrey Leiden, Section 32 and DSM support us in realizing that potential is a huge step for Meatable," said Krijn de Nood, CEO and co-founder of Meatable. "We are honored to welcome a like-minded

group of investors who support us on our mission - to develop, accelerate and bring to life sustainable, healthy and environmentally sound technologies that can improve the human condition. With this funding we believe we are well on our way to bringing our first products to market to sustainably satisfy the world's appetite for natural meat."

Meatable aims to produce cultivated meat, for which no animals are slaughtered, fewer GHG emissions are released, and significantly less land and water are required. And, unlike plantbased alternatives, the end-product will provide the full experience of eating actual meat, with the same texture, taste, and nutritional benefits.

After successfully completing its first pork showcase product, Meatable is currently focused on the further development of cultivated pork and beef. Meatable's technology is adaptable to any cell-based species, including cows, pigs, sheep and fish, giving the company great opportunity for further product development.

###

About Meatable

Meatable is a Dutch cultivated meat company aiming to deliver, at scale, the new natural, cultivated meat that looks like, tastes like, and has the nutritional profile of traditional meat. Its proprietary opti-ox technology enables Meatable to produce the meat rapidly, sustainably, and without harming animals. Founded in 2018 by Krijn de Nood (CEO), Daan Luining (CTO) and Dr. Mark Kotter (principal inventor of opti-ox technology), Meatable has brought together a team of experts with unique knowledge in fields including molecular biology, chemistry, tissue engineering, bioprocess development and food science to create the new natural meat. Follow Meatable: LinkedIn, Facebook, Instagram, Twitter.

Media Contacts:

Hilary McCarthy (US) hilary@clearpointagency.com Phone: +1 774.364.1440

Anke van de Vliet (Europe) anke@weare49stories.com

Note to editors: Facts/figures and photos available upon request

 

 

 

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of 16 companies at the Seed to Series B stage in this rapidly advancing sector. It seeks to secure a 5-10% initial ownership in technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

 

 

About the Cultivated Meat Sector

Funding in the cultivated meat sector is growing rapidly with c US$ 170 million invested globally between 2016-2019 and over US$ 270 million raised in 2020 alone. Additional financings are anticipated as the capital requirements of these companies grows to build out and scale up manufacturing facilities. Currently it is estimated that there are 60 companies globally within the sector. AT Kearney, a global consultancy, has predicted that Cultivated Meat's market share of meat consumption will be 35% by 2040.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR'). Upon the publication of this announcement via a Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain. 

 

For further information please contact:

 

Agronomics

Limited

Beaumont

Cornish Limited

Cenkos

Securities Plc

Peterhouse Capital

Limited

TB Cardew

The Company

Nomad

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Giles Balleny

Nick Searle

Lucy Williams

Charles Goodfellow

Ed Orlebar

Joe McGregor

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 397 8900

+44 (0) 207 469 0936

+44 (0) 20 7930 0777

+44 (0) 7738 724 630

agronomics@tbcardew.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKNBNQBKDBNB
Date   Source Headline
11th Jul 202311:33 amRNSExercise of Warrants and TVR
22nd Jun 20231:06 pmRNSCultivated Meat Approved for Sale in the US
22nd Jun 202312:42 pmRNSPortfolio Company CellX Raises US$ 6.5 million
22nd Jun 202310:00 amRNSGood Dog Food raises investment from Pets at Home
16th Jun 20237:00 amRNSUSDA Gives First Label Approval to Lab Grown Meat
15th Jun 20237:00 amRNSAUD 2.5 million investment in HydGene Renewables
14th Jun 20237:00 amRNSAgronomics Appoints Comms Consultancy
1st Jun 20237:00 amRNSReplacement Warrant Final Exercise Dates Extension
31st May 20237:00 amRNSExtension of Warrant Final Exercise Dates
9th May 20232:08 pmRNSDirectors' Dealings
4th May 20237:00 amRNSInvestee Company Update: Good Dog Food
2nd May 202311:38 amRNSNet Asset Value calculation as at 31 March 2023
14th Apr 202310:19 amRNSExercise of Warrants and TVR
12th Apr 202312:00 pmRNSInvestee Company Update: Liberation Labs
28th Mar 20237:00 amRNSDirector/PDMR Shareholding
27th Mar 202311:50 amRNSDirector/PDMR Shareholding
16th Mar 20237:00 amRNSFood Fermentation Europe launches
15th Mar 20237:00 amRNSDirectors’ interests in shares
10th Mar 20237:15 amRNSEdison issues update on Agronomics (ANIC)
2nd Mar 20235:50 pmRNSHolding(s) in Company
23rd Feb 20238:00 amRNSANIC invests in Wild Microbes US$3.3m Financing
23rd Feb 20237:00 amRNSAgronomics Welcomes Marisa Drew as a Director
20th Feb 20237:00 amRNSPrecision Fermentation Alliance Formed
9th Feb 20239:00 amRNSAgronomics February 2023 Newsletter
8th Feb 20237:00 amRNSUnaudited Interim Results
7th Feb 20234:49 pmRNSInvestee Company Update: CellX
2nd Feb 202311:04 amRNSResult of AGM
25th Jan 20237:00 amRNSNet Asset Value calculation at 31 December 2022
25th Jan 20237:00 amRNSInvestee company Update: Liberation Labs
4th Jan 20237:00 amRNSPerformance Shares issued to Shellbay Investments
30th Dec 202212:00 pmRNSPortfolio Company Update: Liberation Labs
23rd Dec 20227:00 amRNSSolar Foods receives Euro34 million in grant
20th Dec 20229:00 amRNSFinal Results
5th Dec 20229:18 amRNSInvestee Company Update: Clean Food Group
5th Dec 20227:00 amRNSFurther Investment in Liberation Labs Seed Round
28th Nov 20227:00 amRNSHolding(s) in Company
23rd Nov 20225:59 pmRNSHolding(s) in Company
17th Nov 20227:30 amRNSFirst Cultivated Meat Company gets FDA approval
3rd Nov 20227:00 amRNSAgronomics Capital Markets Day 3rd November
27th Oct 202212:02 pmRNSDirector Dealings
26th Oct 20229:30 amRNSPortfolio Company Solar Foods Update
20th Oct 20227:00 amRNSInvestment in Liberation Labs US$ 20m fundraise
19th Oct 20229:00 amRNSAgronomics October 2022 Newsletter
19th Oct 20227:00 amRNSNet Asset Value calculation to 30 September 2022
12th Oct 20228:53 amRNSHolding(s) in Company
11th Oct 20227:00 amRNSExercise of Warrants & TVR
10th Oct 20227:00 amRNSPortfolio Company Meatable Update
6th Oct 20227:00 amRNSPortfolio Company VitroLabs Update
26th Sep 20228:48 amRNSEdison issues flash on Agronomics (ANIC)
21st Sep 20227:00 amRNSPortfolio Company Update: Onego Bio

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.